РОЛЬ СПІВВІДНОШЕННЯ PLGF/SFLT-1 У ПРОГНОЗУВАННІ ПРЕЕКЛАМПСІЇ (ОГЛЯД ЛІТЕРАТУРИ)

Anastasiіa Padchenko; Irina Venzkovskaya

doi:10.32345/USMYJ.1(109).2019.25-34

Anastasiіa Padchenko obstetrician-gynecologist of the Kyiv City Perinatal Center.
Irina Venzkovskaya MD, prof. of the Obstetrics and Gynecology Department No 1 of Bohomolets National Medical University.

DOI: https://doi.org/10.32345/USMYJ.1(109).2019.25-34

Keywords: angiogenesis, endothelial dysfunction, hypertension, placental growth factor (PlGF), preeclampsia, soluble fms-like tyrosine kinase-1 (sFlt-1).

Abstract

Endothelial vascular dysfunction is an important link in the pathogenesis of preeclampsia – a pathological condition that occupies a leading position in the structure of maternal morbidity and mortality, perinatal mortality and intrauterine growth retardation. Assessment of the state of vascular endothelium during pregnancy is currently an informative method for predicting the development of this disease. The article summarizes the significance of the most studied specific biochemical markers of endothelial dysfunction, such as soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), in relation to the prognosis and diagnosis of preeclampsia. Since the etiopathogenesis of preeclampsia is caused by the development of endothelial insufficiency and impaired vascular formation in the mother-placenta-fetus system, the choice of angiogenesis biomarkers as screening tests is justified from a logical point of view. As a screening indicator of the risk of preeclampsia, the most reliable determination of the ratio sFlt-l/PIGF, which reflects the change in both biomarkers during preeclampsia, is more pronounced than a separate definition of any of these factors. In women with the pathological course of the gestational process, in several weeks before the onset of the first clinical symptoms, a decrease in PlGF concentration and a significant increase in sFlt-1 concentration are observed in 92.5% of cases, which makes it possible to determine the risk of gestosis long before the onset of its severe clinical manifestations and to develop an optimal management for patients with this pathology. This topic is relevant, since the prevalence of preeclampsia according to different authors varies from 3 to 8% among pregnant women in developed countries. In general, up to 10-15% of maternal deaths are associated with preeclampsia and eclampsia.

References

Brosens, I., Pijnenborg, R., Vercruysse, L., & Romero, R. (2011). The “Great Obstetrical Syndromes” are associated with disorders of deep placentation. American journal of obstetrics and gynecology, 204(3), 193-201.

Carty, D. M., Delles, C., & Dominiczak, A. F. (2010). Preeclampsia and future maternal health. Journal of hypertension, 28(7), 1349-1355.

Cerdeira, A. S., & Karumanchi, S. A. (2010). Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. Scandinavian Journal of Clinical and Laboratory Investigation, 70(sup242), 73-78.

Chandiramani, M. A. N. J. U., Waugh, J. J. S., & Shennan, A. H. (2007). Management of hypertension and pre‐eclampsia in pregnancy. Trends in Urology, Gynaecology & Sexual Health, 12(3), 23-28.

Duley, L. (2009, June). The global impact of pre-eclampsia and eclampsia. In Seminars in perinatology (Vol. 33, No. 3, pp. 130-137). WB Saunders.

Giguère, Y., Charland, M., Thériault, S., Bujold, E., Laroche, M., Rousseau, F., ... & Forest, J. C. (2012). Linking preeclampsia and cardiovascular disease later in life. Clinical chemistry and laboratory medicine, 50(6), 985-993.

Grill, S., Rusterholz, C., Zanetti-Dällenbach, R., Tercanli, S., Holzgreve, W., Hahn, S., & Lapaire, O. (2009). Potential markers of preeclampsia–a review. Reproductive biology and endocrinology, 7(1), 70.

Kvehaugen, A. S., Dechend, R., Ramstad, H. B., Troisi, R., Fugelseth, D., & Staff, A. C. (2011). Endothelial function and circulating biomarkers are disturbed in women and children after preeclampsia. Hypertension, 58(1), 63-69.

Lam, C., Lim, K. H., & Karumanchi, S. A. (2005). Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension, 46(5), 1077-1085.

Leaños-Miranda, A., Méndez-Aguilar, F., Ramírez-Valenzuela, K. L., Serrano-Rodríguez, M., Berumen-Lechuga, G., Molina-Pérez, C. J., ... & Campos-Galicia, I. (2017). Circulating angiogenic factors are related to the severity of gestational hypertension and preeclampsia, and their adverse outcomes. Medicine, 96(4).

Levine, R. J., Maynard, S. E., Qian, C., Lim, K. H., England, L. J., Yu, K. F., ... & Sibai, B. M. (2004). Circulating angiogenic factors and the risk of preeclampsia. New England journal of medicine, 350(7), 672-683.

Lyatoshinskaya, P., Faichtinger, W., Hafner, E., Zeisler, H., & Skodler, W. (2012). Риск и течение преэклампсии во время беременности после ЭКО или ИКСИ (перевод К. Муминовой). Проблемы репродукции, (5), 59-63.

Maynard, S. E., Min, J. Y., Merchan, J., Lim, K. H., Li, J., Mondal, S., ... & Epstein, F. H. (2003). Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. The Journal of clinical investigation, 111(5), 649-658.

McElrath, T. F., Lim, K. H., Pare, E., Rich-Edwards, J., Pucci, D., Troisi, R., & Parry, S. (2012). Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. American journal of obstetrics and gynecology, 207(5), 407-e1.

Meloni, P., D'Angeli, I., Piazze, J., Cerekya, A., Simari, T., Pala, A., ... & Izzo, L. (2009). First trimester PAPP-A levels associated with early prediction of pregnancy induced hypertension. Hypertension in pregnancy, 28(4), 361-368.

Myers, J. E., Kenny, L. C., McCowan, L. M. E., Chan, E. H. Y., Dekker, G. A., Poston, L., ... & North, R. A. (2013). Angiogenic factors combined with clinical risk factors to predict preterm pre‐eclampsia in nulliparous women: a predictive test accuracy study. BJOG: An International Journal of Obstetrics & Gynaecology, 120(10), 1215-1223.

Husse, S., Gottschlich, A., Schrey, S., Stepan, H., & Hoffmann, J. (2014). Predictive value of the sFlt1/PlGF ratio for the diagnosis of preeclampsia in high-risk patients. Zeitschrift fur Geburtshilfe und Neonatologie, 218(1), 34-41.

Palm, M., Basu, S., Larsson, A., Wernroth, L., Åkerud, H., & Axelsson, O. (2011). A longitudinal study of plasma levels of soluble fms‐like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF‐A) in normal pregnancy. Acta obstetricia et gynecologica Scandinavica, 90(11), 1244-1251.

Sánchez-Aranguren, L. C., Prada, C. E., Riaño-Medina, C. E., & Lopez, M. (2014). Endothelial dysfunction and preeclampsia: role of oxidative stress. Frontiers in physiology, 5, 372.

Serov, V. N., Kan, N. E., & Tyutyunik, V. L. (2016). Prognosticvalue of ratio of soluble fms like tyrokinase 1 to placental growth factor in pregnant women with preeclampsia. Obstetrics and Gynecology, 6, 5-10.

Shibata, E., Rajakumar, A., Powers, R. W., Larkin, R. W., Gilmour, C., Bodnar, L. M., ... & Hubel, C. A. (2005). Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. The Journal of Clinical Endocrinology & Metabolism, 90(8), 4895-4903.

Stepan, H., Geipel, A., Schwarz, F., Krämer, T., Wessel, N., & Faber, R. (2008). Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. American journal of obstetrics and gynecology, 198(2), 175-e1.

Stepan, H., Unversucht, A., Wessel, N., & Faber, R. (2007). Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension, 49(4), 818-824.

Tkachenko, O., Shchekochikhin, D., & Schrier, R. W. (2014). Hormones and hemodynamics in pregnancy. International journal of endocrinology and metabolism, 12(2).

Uzan, J., Carbonnel, M., Piconne, O., Asmar, R., & Ayoubi, J. M. (2011). Pre-eclampsia: pathophysiology, diagnosis, and management. Vascular health and risk management, 7, 467.

Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., Moertl, M. G., ... & Stepan, H. (2010). An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. American journal of obstetrics and gynecology, 202(2), 161-e1.

Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Moertl, M., Zeisler, H., ... & Denk, B. (2012). The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. American journal of obstetrics and gynecology, 206(1), 58-e1.

Wang, A., Rana, S., & Karumanchi, S. A. (2009). Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology, 24(3), 147-158.

Wikström, A. K., Larsson, A., Eriksson, U. J., Nash, P., Nordén-Lindeberg, S., & Olovsson, M. (2007). Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstetrics & Gynecology, 109(6), 1368-1374.

Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., ... & Dilba, P. (2016). Predictive value of the sFlt-1: PlGF ratio in women with suspected preeclampsia. New England Journal of Medicine, 374(1), 13-22.

Иванец, Т. Ю., Алексеева, М. Л., Логинова, Н. С., Колодько, В. Г., Насонова, Д. М., & Хасьянова, З. Ш. (2013). Плацентарный фактор роста и FMS-подобная тирозинкиназа-1 как маркеры преэклампсии в динамике беременности. Клиническая лабораторная диагностика, (8).

Иванец, Т. Ю., Алексеева, М. Л., Гончарова, Е. А., Ходжаева, З. С., & Вавина, О. В. (2012). Маркеры преэклампсии в I и II триместрах беременности. Проблемы репродукции, (3), 83-87.

Макаров, О. В., Волкова, Е. В., Лысюк, Е. Ю., Копылова, Ю. В., & Джохадзе, Л. С. (2014). Роль ангиогенных факторов роста в патогенезе преэклампсии и плацентарной недостаточности. Акушерство и гинекология, (12), 64-70.

Радзинский, В. Е., Оразмурадов, А. А. (2009). Ранние сроки беременности (2-е изд., испр. и доп.)/Под ред. Радзинского В. Е, Оразмурадова АА-М.: Status Praesens.

Сидорова, И. С., Макаров, И. О., Солоницын, А. Н., Боровкова, Е. И., & Билявская, О. С. (2009). Характер изменений маркеров ангиогенеза при гестозе. Акушерство и гинекология, (3), 38-41.

THE ROLE OF THE PIGF/SFLT-1 RELATIONSHIP IN PREDICTING PREECLAMPSIA (LITERATURE REVIEW)

Abstract

References